Current problems with tuberculosis treatment

Research in Microbiology

Volumn 147, Issue 1-2, 1996, Pages 10-16

  Grosset, J ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; PYRAZINAMIDE; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

CHEMOTHERAPY; CONFERENCE PAPER; HEALTH CARE ORGANIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; TUBERCULOSIS;

EID: 0029969559     PISSN: 09232508     EISSN: None     Source Type: Journal    
DOI: 10.1016/0923-2508(96)80197-5     Document Type: Conference Paper

References (32)

1. Algerian Working Group/British Medical Research Council Cooperative Study (1984), Controlled clinical trial comparing a 6-month and a 12-month regimen in the treatment of pulmonary tuberculosis in the Algerian Sahara. Am. Rev. Respir. Dis., 129, 921-928.
2. American Thoracic Society (1994), Treatment of tuberculosis and tuberculosis infection in Adults and Children. Am. J. Respir. Crit. Care Med., 149, 1359-1374.
3. American Thoracic Society and the Centers for Disease Control. (1986), Treatment of tuberculosis and tuberculosis infection in adults and children. Am. Rev. Respir. Dis., 134, 355-363.
4. Bates, J.H. (1995), Tuberculosis chemotherapy. The need for new antituberculosis drugs is urgent. Am. J. Respir. Crit. Care med., 151, 942-943.
5. Bernstein, J., Lott, W.A., Steinberg, B.A. & Yale, H.L. (1952), Chemotherapy of experimental tuberculosis -V. Isonicotinic acid hydrazide (Nydrazid) and related compounds. Am. Rev. Tuberc., 65, 357-64.
6. British Thoracic Society (1984), A controlled trial of 6 months chemotherapy in pulmonary tuberculosis. Final report: results during the 36 months after the end of chemotherapy and beyond. Br. J. Dis. Chest., 78, 330-336.
7. British Thoracic and Tuberculosis Association (1976), Short-course chemotherapy in pulmonary tuberculosis: a controlled trial. Lancet, 2, 1102-1104.
8. Canetti, G. (1959), Modifications des populations des foyers tuberculeux au cours de la chimiothérapie antibacillaire. Ann. Inst. Pasteur., 97, 53-79.
9. Canetti, G. & Grosset, J. (1961), Teneur des souches sauvages de Mycobacterium tuberculosis en variants résistants à l'isoniazide et en variants résistants à la streptomycine sur milieu de Löwenstein-Jensen. Ann. Inst. Pasteur, 101, 28-46.
10. Centers for Disease Control (1992), Management of persons exposed to multidrug-resistant tuberculosis. MMWR, 41, 59-71.
11. Centers for Disease Control (1993), Estimates of future global tuberculosis morbidity and mortality. MMWR, 42, 961-964.
12. Chaulet, P. (1983), La chimiothérapie de la tuberculose en 1983, Bull. Int. Union Tuberc., 58, 26-36.
13. Datta, M., Radhamani, M.P., Selvaraj, R., Paramasivan, C.N., Gopalan, B.N., Sudeendra, C.R. & Prabhakar, R. (1993), Critical assessment of smear-positive pulmonary tuberculosis patients after chemotherapy under the district tuberculosis programme. Tubercle Lung Dis., 74, 180-186.
14. East African/British Medical Research Councils (1972), Controlled clinical trial of short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Lancet, 1, 1079-85.
15. Etude Internationale sur l'efficacité de la chimiothérapie (1964), Bull. Int. Union. Tuberc., 44, 81-202.
16. Farga, V., Valenzuela, P., Mendoza, F., Torres, E., Icekson, I., Grinspun, M., Fernandez, M., Corradini, A., Martinez, M., Velasco, J. et al. (1983), Trials in Chile. Bull. Int. Union Tuberc., 58, 102-107.
17. Frieden, T.R., Fujiware, P.I., Hamburg, M.A., Ruggiero, D., Henning, K.J. (1994), Tuberculosis Clinics. Am. J. Respir. Crit. Care Med., 150, 893-894.
18. Frieden, T.R., Fujiwara, P.I., Washko, R.M. & Hamburg, M.A. (1995), Tuberculosis in New York City - Turning the tide. Special article. N. Engl. J. Med., 333, 229-233.
19. Grosset, J. (1980), Bacteriologic basis of short-course chemotherapy for tuberculosis. Clin. Chest. Med., 1, 231-41.
20. Grumbach, F. & Rist, N. (1967), Activité antituberculeuse expérimentale de la rifampicine, dérivé de la rifamycine SV. Rev. Tuberc. Pneum., 31, 749-762.
21. Grzybowski, S. & Enarson, D.A. (1978), Results of pulmonary tuberculosis patients under various treatment program conditions. Bull. Int. Union Tuberc., 53, 70-75.
22. Grzybowski, S. (1993), Drugs are not enough. Tubercle Lung Dis., 74, 145-146.
23. Hopewell, P.C. (1994), The baby and the bath water. The case for retaining categorical services for tuberculosis control in a reformed health care system. Am. J. Respir. Crit. Care Med., 150, 895.
24. Lehmann, J. (1946), Para-aminosalicylic acid in the treatment of tuberculosis. Lancet., 1, 15-16.
25. Mackaness, G.B. (1956), The intracellular activation of pyrazinamide and nicotinamide. Am. Rev. Tuberc., 74, 718-28.
26. Medical Research Council Investigation (1948), Streptomycin treatment of pulmonary tuberculosis. Br. Med. J., 2, 769-782.
27. Medical Research Council Investigation (1950), Treatment of pulmonary tuberculosis with streptomycin and para-aminosalicylic acid. Br. Med. J., 2, 1073-1086.
28. Medical Research Council-Tuberculosis Chemotherapy Trials Commitee (1962), Long-term chemotherapy in the treatment of chronic pulmonary tuberculosis with cavitation. Tubercle, 43, 201-267.
29. Murray, C.J.L., Dejonghe, E., Chum, H.J., Nyangulu, D.S., Salomao, A. & Styblo, K. (1991), Cost effectiveness of chemotherapy for pulmonary tuberculosis in three sub-Saharan African countries. Lancet, 338, 1305-1308.
30. Sepkowitz, K.A., Raffalli, J., Riley, L., Kiehn, T.E. & Armstrong, D. (1995), Tuberculosis in the AIDS era. Clin. Microbiol. Rev., 8, 180-199.
31. Société Française de Pneumologie (1984), Recommandations pour le traitement de la tuberculose en France. Rev. Fr. Mal. Respir., 1, 59-62.
32. Trial 6, 9, 12, (1977), General report: overall methods and results. Rev. Fr. Mal. Respir., 5 (Suppl. 1), 3-63.